Search "FDA peptide ban 2026" and you'll find two stories that can't both be true. One says peptides got banned. The other says BPC-157 just got approved because an FDA panel voted 8 to 6 in July. Most people pick one and move on. Neither one happened.
There was no ban, and there was no approval
Both stories come from one narrow rule about what pharmacies may mix. An FDA advisory vote is a recommendation, not a decision. The FDA decides later whether to act on it. As of October 2026 it hasn't, and nothing has legally changed for any of the six peptides the panel recommended.
The proof: what the 2026 peptide ban really was
Let's get into it.
The "ban" was a pharmacy rule. Compounding is when a licensed pharmacy mixes a drug for one patient with a prescription. In 2023 the FDA put a long list of peptides in what it calls Category 2, meaning compounding pharmacies may not make them. On April 22, 2026, twelve came off that list, including BPC-157, TB-500 and injectable GHK-Cu, after the groups that nominated them withdrew (FDA, Category 2 list). Off one list isn't on another. It just means each one gets its own review. (Kisspeptin-10 didn't come off. It's still there.)
Then the panel outvoted the FDA's own reviewers. On July 23 and 24, the Pharmacy Compounding Advisory Committee (PCAC, a group of outside experts) looked at seven peptides. FDA staff had recommended against all seven. Their BPC-157 review said the evidence weighed against adding it (FDA briefing document). The panel said yes anyway, 8 to 6 with one abstention. It also backed KPV, TB-500, MOTS-c, epitalon and semax. The only no was emideltide, also called DSIP, voted down 7 to 6 (AJMC, July 2026).
The FDA's own page says it plainly. Advisory committees make "non-binding recommendations" (FDA, PCAC meeting page). Picture a book club voting on what the library should buy. The vote is real. The book still isn't on the shelf. If the FDA agrees, formal rulemaking comes next. Even then, the best case is a pharmacy making it with a prescription. Not an approved drug.
So why should you care? Because "the FDA voted" is already a sales line. A page that calls a compound "now legal" or "FDA approved" read the headline, not the meeting page. That tells you how carefully it reads its own paperwork.
"But doesn't a research-use-only label settle it?" Nope. On March 31, 2026 the FDA signed warning letters to five online peptide sellers whose products carried research-use-only labels. In one, it wrote that evidence from the seller's own website established the products were drugs for human use (FDA warning letter to Gram Peptides). On August 24 it signed five more. The label doesn't decide what a product is. The whole website does.
The big learning lesson
Keep reading: Why BPC-157 and TB-500 are studied together · How to choose a research peptide supplier · Semax vs Selank compared
Frequently asked questions
Did the FDA ban peptides in 2026?
No. The "ban" people talk about is Category 2, a rule about what licensed pharmacies may compound. In April 2026 twelve peptides came off that list, and kisspeptin-10 is still on it.
Did the FDA approve BPC-157?
No. On July 23, 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend BPC-157 for the pharmacy compounding list. That's a non-binding recommendation, not a drug approval, and as of October 2026 the FDA hasn't acted on it.
Which peptides did the FDA panel recommend in July 2026?
Six: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. It voted against emideltide, also known as DSIP.